HAL
50
-4
SHW
58
12
BRK.B
47
-3
NWL
33
11
ROK
46
3
AON
23
-9
PX
15
2
ETR
58
-2
MET
45
5
PRGO
66
9
PWR
76
2
KLAC
65
6
AXP
74
-3
CINF
41
-9
DTE
40
-2
CTAS
55
2
CRM
49
5
HAS
57
-3
MAC
71
4
LLY
56
2
HAL
50
-4
SHW
58
12
BRK.B
47
-3
NWL
33
11
ROK
46
3
AON
23
-9
PX
15
2
ETR
58
-2
MET
45
5
PRGO
66
9
PWR
76
2
KLAC
65
6
AXP
74
-3
CINF
41
-9
DTE
40
-2
CTAS
55
2
CRM
49
5
HAS
57
-3
MAC
71
4
LLY
56
2
Financhill
Back

Keros Therapeutics Quote, Financials, Valuation and Earnings

My #1 Coin is...

All the details are on the next page.
Sell
32

KROS
Keros Therapeutics

Last Price:
57.84
Seasonality Move:
-16.78%

7 Day Trial

ALL ACCESS PASS

$ 7

The little-known AI stock you need to read about now...

Get the name - FREE.

Keros Therapeutics Price Quote

$57.84
-0.02 (6.74%)
(Updated: April 27, 2024 at 4:44 AM ET)

Keros Therapeutics Key Stats

Sell
32
Keros Therapeutics (KROS) is a Sell
Day range:
$53.69 - $58.45
52-week range:
$27.02 - $73.00
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
6.27%
Volume:
291.8K
Avg. volume:
338.8K
1-year change:
33.04%
Market cap:
$2.1B
Revenue:
$151K
EPS:
$-5.2

How Much Does Keros Therapeutics Make?

Data Unavailable

Is Keros Therapeutics Growing As A Company?

Data Unavailable

Keros Therapeutics Stock Price Performance

What Is Keros Therapeutics 52-Week High & Low?

Keros Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Keros Therapeutics?

Is Keros Therapeutics Cash Flow Positive?

  • What Is KROS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$124.5M
  • What Is Keros Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $179M
  • What Is Keros Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$2.5M

Keros Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    KROS return on invested capital is -48.21%
  • What Is Keros Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -43.87%
  • What Is KROS Return On Equity?
    ROE is a measure of profitability and is -48.21%

Keros Therapeutics Earnings Date & Stock Price

Keros Therapeutics Competitors

  • Who Are Keros Therapeutics's Competitors?
    Below is a list of companies who compete with Keros Therapeutics or are related in some way:
    • Morphic Holding Inc (MORF)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)
    • Regeneron Pharmaceuticals Inc (REGN)
    • Scholar Rock Holding Corp (SRRK)

Keros Therapeutics Dividend Yield

Data Unavailable

Keros Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 3.68%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 8
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 88.11
Upside from Last Price: 52.28%

Major Shareholders

  • How many KROS shares are owned by institutional investors?
    42M KROS shares are owned by institutional investors
  • How many KROS shares are owned by insiders?
    372.2K KROS shares are owned by insiders